ICON Q3 profits surge by 42% to $8.8m

ICON, the listed clinical trials company, has reported a 42% surge in third quarter pre-tax profits helped by a strong pipeline of new business wins.

The company, which undertakes clinical research for biotech and pharmaceutical companies, said the three months to end February pre-tax profits had risen from $6.3 million to $8.8m.

Third quarter revenues rose by 29% to $76.8 million.